Cardiovascular Journal of Africa: Vol 32 No 6 (NOVEMBER/DECEMBER 2021)

CARDIOVASCULAR JOURNAL OF AFRICA • Volume 32, No 6, November/December 2021 AFRICA 337 facilitates earlier conversion of atrial fibrillation compared to amiodar- one-only therapy. Pacing Clin Electrophysiol 2017; 40 (4): 372–378. 69. Koskinas KC, Fragakis N, Katritsis D, Skeberis V, Vassilikos V. Ranolazine enhances the efficacy of amiodarone for conversion of recent-onset atrial fibrillation. Europace 2014; 16 (7): 973–979. 70. Van Gelder IC, Crijns HJ, Van Gilst WH, Verwer R, Lie KI. Prediction of uneventful cardioversion and maintenance of sinus rhythm from direct-current electrical cardioversion of chronic atrial fibrillation and flutter. Am J Cardiol 1991; 68 (1): 41–46. 71. Frick M, Frykman V, Jensen-Urstad M, Östergren J. Factors predict- ing success rate and recurrence of atrial fibrillation after first electrical cardioversion in patients with persistent atrial fibrillation. Clin Cardiol 2001; 24 (3): 238–244. 72. Tieleman RG, van Gelder IC, Crijns HJGM, De Kam PJ, van den Berg MP, Haaksma J, et al . Early recurrences of atrial fibrillation after electri- cal cardioversion: A results of fibrillation-induced electrical remodeling of the atria? J Am Coll Cardiol 1998; 31 (1): 167–173. 73. Doyle JF, Ho KM. Benefits and risks of long-term amiodarone therapy for persistent atrial fibrillation: a meta-analysis. Mayo Clin Proc 2009; 84 (3): 234-242. 74. Channer KS, Birchall A, Steeds RP, Walters SJ, Yeo WW, West JN, et al . A randomized placebo-controlled trial of pre-treatment and short- or long-term maintenance therapy with amiodarone supporting DC cardioversion for persistent atrial fibrillation. Eur Heart J 2004; 25 (2): 144–150. 75. Capucci A, Villani GQ, Aschieri D, Rosi A, Piepoli MF. Oral amiodar- one increases the efficacy of direct-current cardioversion in restoration of sinus rhythm in patients with chronic atrial fibrillation. Eur Heart J 2000; 21 (1): 66–73. 76. Galperin J, Elizari M V, Bonato R, Ledesma R, Vazquez Blanco M, Lago M, et al . Short-term amiodarone therapy after reversion of persis- tent atrial fibrillation reduces recurrences at 18 months. Cardiol J 2014; 21 (4): 397–404. 77. Jong G, Chang M, Chang T, Chou P, Fu C, Tien L, et al. Long-term efficacy and safety of very-low-dose amiodarone treatment for the maintenance of sinus rhythm in patients with chronic atrial fibrillation after successful direct-current cardioversion. Chin Med J (Engl) 2006; 119 (24): 2030–2035. 78. Boos C, Ritzema J, More RS. A short course of oral amiodarone improves sinus rhythm maintenance post-cardioversion for atrial fibril- lation. Heart 2004; 90 (9): 1063-1064. 79. Galperin J, Elizari M V, Chiale PA, Molina RT, Ledesma R, Scapin AO, et al . Efficacy of amiodarone for the termination of chronic atrial fibrillation and maintenance of normal sinus rhythm: a prospective, multicenter, randomized, controlled, double blind trial. J Cardiovasc Pharmacol Ther 2001; 6 (4): 341–350. 80. Deedwania PC, Singh BN, Ellenbogen K, Fisher S, Fletcher R, Singh SN. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observa- tions from the veterans affairs congestive heart failure survival trial of antiarrhythmic therapy (CHF-STAT). Department of Veterans Affairs CHF-STAT Investigators. Circulation 1998; 98 (23): 2574–2579. 81. Opolski G, Stanisławska J, Górecki A, Swiecicka G, Torbicki A, Kraska T. Amiodarone in restoration and maintenance of sinus rhythm in patients with chronic atrial fibrillation after unsuccessful direct-current cardioversion . Clin Cardiol 1997; 20 (4): 337–340. 82. Chun SH, Sager PT, Stevenson WG, Nademanee K, Middlekauff HR, Singh BN. Long-term efficacy of amiodarone for the maintenance of normal sinus rhythm in patients with refractory atrial fibrillation or flutter. Am J Cardiol 1995; 76 (1): 47–50. 83. Gosselink AT, Crijns HJ, Van Gelder IC, Hillige H, Wiesfeld AC, Lie KI. Low-dose amiodarone for maintenance of sinus rhythm after cardioversion of atrial fibrillation or flutter. J Am Med Assoc 1992; 267 (24): 3289–3293. 84. Brodsky MA, Allen BJ, Walker CJ 3rd, Casey TP, Luckett CR, Henry WL. Amiodarone for maintenance of sinus rhythm after conversion of atrial fibrillation in the setting of a dilated left atrium. Am J Cardiol 1987; 60 (7): 572–575. 85. Gold RL, Haffajee CI, Charos G, Sloan K, Baker S, Alpert JS. Amiodarone for refractory atrial fibrillation. Am J Cardiol 1986; 57 (1): 124–127. 86. Horowitz LN, Spielman SR, Greenspan AM, Mintz GS, Morganroth J, Brown R, et al . Use of amiodarone in the treatment of persistent and paroxysmal atrial fibrillation resistant to quinidine therapy. J Am Coll Cardiol 1985; 6 (6): 1402–1407. 87. Ganesan AN, Shipp NJ, Brooks AG, Kuklik P, Lau DH, Lim HS, et al. Long-term outcomes of catheter ablation of atrial fibrillation: a system- atic review and meta-analysis . J Am Heart Assoc 2013: 2 (2): e004549. 88. Steven D, Sultan A, Reddy V, Luker J, Altenburg M, Hoffmann B, et al . Benefit of pulmonary vein isolation guided by loss of pace capture on the ablation line: Results from a prospective 2-center randomized trial. J Am Coll Cardiol 2013; 62 (1): 44–50. 89. Brooks AG, Stiles MK, Laborderie J, Lau DH, Kuklik P, Shipp NJ, et al . Outcomes of long-standing persistent atrial fibrillation ablation: A systematic review. Heart Rhythm 2010; 7 (6): 835–846. 90. Andrade JG, Khairy P, Verma A, Guerra PG, Dubuc M, Rivard L, et al . Early recurrence of atrial tachyarrhythmias following radiofrequency catheter ablation of atrial fibrillation. Pacing Clinl Electrophysiol 2012: 35 (1): 106–116. 91. Kuck KH, Wissner E. Why amiodarone failed to lower the rate of recur- rence six months after catheter ablation for atrial fibrillation . Eur Heart J 2014; 35 (47): 3321–3322. 92. Goldenberg GR, Burd D, Lodzinski P, Stabile G, Udell JA, Newman D, et al . Antiarrhythmic therapy as an adjuvant to promote post pulmo- nary vein isolation success – a meta-analysis. J Interv Card Electrophysiol 2016; 47 (2): 171–176. 93. Duytschaever M, Demolder A, Phlips T, Sarkozy A, El Haddad M, Taghji P, et al . PulmOnary vein isolation With vs. without continued antiarrhythmic Drug trEatment in subjects with Recurrent Atrial Fibrillation (POWDER AF): results from a multicentre randomized trial. Eur Heart J 2018; 39 (16): 1429–1437. 94. Kettering K, Gramley F. Catheter ablation of persistent atrial fibrilla- tion: Beneficial effect of a short-term adjunctive amiodarone therapy on the long-term outcome. Herzschrittmacherther Elektrophysiol 2018; 29 (1): 133–140. 95. Kaitani K, Inoue K, Kobori A, Nakazawa Y, Ozawa T, Kurotobi T, et al . Efficacy of Antiarrhythmic drugs Short-Term use after catheter ablation for Atrial Fibrillation (EAST-AF) trial. Eur Heart J 2016; 37 (7): 610–618. 96. Darkner S, Chen X, Hansen J, Pehrson S, Johannessen A, Nielsen JB, et al . Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, rand- omized, placebo-controlled study (AMIO-CAT trial). Eur Heart J 2014; 35 (47): 3356–3364. 97. Lodzi ń ski P, Kiliszek M, Ko ź luk E, Pi ą tkowska A, Balsam P, Kochanowski J, et al . Does a blanking period after pulmonary vein isolation impact long-term results? Results after 55 months of follow-up. Cardiol J 2014; 21 (4): 384–391. 98. Mohanty S, Di Biase L, Mohanty P, Trivedi C, Santangeli P, Bai R, et al . Effect of periprocedural amiodarone on procedure outcome in patients